Which has higher valuation & earnings, BLTE or GPCR?

Belite Bio is trading at a lower price-to-earnings ratio than Structure Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Belite Bio N/A N/A -$77.61M -$2.73 N/A Structure Therapeutics N/A N/A -$141.20M -$1.00 N/A

Is BLTE or GPCR more profitable?

Belite Bio's return on equity of -11.84% beat Structure Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Belite Bio N/A -11.84% -11.62% Structure Therapeutics N/A -25.56% -24.31%

Does the media prefer BLTE or GPCR?

In the previous week, Belite Bio had 3 more articles in the media than Structure Therapeutics. MarketBeat recorded 5 mentions for Belite Bio and 2 mentions for Structure Therapeutics. Belite Bio's average media sentiment score of 0.39 beat Structure Therapeutics' score of 0.36 indicating that Belite Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Structure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to AMRX or GPCR?

In the previous week, Amneal Pharmaceuticals had 5 more articles in the media than Structure Therapeutics. MarketBeat recorded 7 mentions for Amneal Pharmaceuticals and 2 mentions for Structure Therapeutics. Amneal Pharmaceuticals' average media sentiment score of 0.38 beat Structure Therapeutics' score of 0.36 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Structure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer GPCR or LNTH?

In the previous week, Lantheus had 1 more articles in the media than Structure Therapeutics. MarketBeat recorded 3 mentions for Lantheus and 2 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 0.36 beat Lantheus' score of 0.00 indicating that Structure Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Lantheus 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to LQDA or GPCR?

In the previous week, Liquidia had 30 more articles in the media than Structure Therapeutics. MarketBeat recorded 32 mentions for Liquidia and 2 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 0.36 beat Liquidia's score of -0.12 indicating that Structure Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 4 Very Positive mention(s) 6 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Structure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Structure Therapeutics (GPCR) Competitors

$25.54 -0.13 (-0.51%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$25.64 +0.10 (+0.37%)

As of 10/9/2026 07:57 PM Eastern

Compare

GPCR vs. CRNX, BLTE, AMRX, LNTH, and LQDA

Should you buy Structure Therapeutics stock or one of its competitors? Structure Therapeutics's main competitors and comparable companies include Crinetics Pharmaceuticals (CRNX), Belite Bio (BLTE), Amneal Pharmaceuticals (AMRX), Lantheus (LNTH), and Liquidia (LQDA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Structure Therapeutics compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Structure Therapeutics (NASDAQ:GPCR) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are owned by insiders. Comparatively, 5.5% of Structure Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Structure Therapeutics has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Structure Therapeutics' return on equity of -25.56% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%
Structure Therapeutics	N/A	-25.56%	-24.31%

In the previous week, Structure Therapeutics had 2 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 2 mentions for Structure Therapeutics and 0 mentions for Crinetics Pharmaceuticals. Structure Therapeutics' average media sentiment score of 0.36 beat Crinetics Pharmaceuticals' score of 0.00 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Crinetics Pharmaceuticals	Neutral
Structure Therapeutics	Neutral

Crinetics Pharmaceuticals has a beta of 0.08, indicating that its stock price is 92% less volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.3, indicating that its stock price is 230% less volatile than the broader market.

Structure Therapeutics has lower revenue, but higher earnings than Crinetics Pharmaceuticals. Structure Therapeutics is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$7.70M	1,170.54	-$465.32M	-$5.04	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A

Crinetics Pharmaceuticals currently has a consensus target price of $83.44, indicating a potential downside of 1.77%. Structure Therapeutics has a consensus target price of $110.91, indicating a potential upside of 334.26%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Structure Therapeutics is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.82

Summary

Structure Therapeutics beats Crinetics Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Structure Therapeutics compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Structure Therapeutics (NASDAQ:GPCR) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

Belite Bio presently has a consensus price target of $218.73, indicating a potential upside of 41.58%. Structure Therapeutics has a consensus price target of $110.91, indicating a potential upside of 334.26%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Structure Therapeutics is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.82

0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by insiders. Comparatively, 5.5% of Structure Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Belite Bio has a beta of -1.23, indicating that its stock price is 223% less volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.3, indicating that its stock price is 230% less volatile than the broader market.

Belite Bio is trading at a lower price-to-earnings ratio than Structure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A

Belite Bio's return on equity of -11.84% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-11.84%	-11.62%
Structure Therapeutics	N/A	-25.56%	-24.31%

In the previous week, Belite Bio had 3 more articles in the media than Structure Therapeutics. MarketBeat recorded 5 mentions for Belite Bio and 2 mentions for Structure Therapeutics. Belite Bio's average media sentiment score of 0.39 beat Structure Therapeutics' score of 0.36 indicating that Belite Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Structure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Belite Bio and Structure Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Structure Therapeutics compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Structure Therapeutics (NASDAQ:GPCR) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

Amneal Pharmaceuticals has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.3, meaning that its stock price is 230% less volatile than the broader market.

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by insiders. Comparatively, 5.5% of Structure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Amneal Pharmaceuticals has a net margin of 5.05% compared to Structure Therapeutics' net margin of 0.00%. Structure Therapeutics' return on equity of -25.56% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
Structure Therapeutics	N/A	-25.56%	-24.31%

Amneal Pharmaceuticals presently has a consensus target price of $21.00, suggesting a potential upside of 5.47%. Structure Therapeutics has a consensus target price of $110.91, suggesting a potential upside of 334.26%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Structure Therapeutics is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.82

In the previous week, Amneal Pharmaceuticals had 5 more articles in the media than Structure Therapeutics. MarketBeat recorded 7 mentions for Amneal Pharmaceuticals and 2 mentions for Structure Therapeutics. Amneal Pharmaceuticals' average media sentiment score of 0.38 beat Structure Therapeutics' score of 0.36 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Structure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Amneal Pharmaceuticals has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	2.11	$72.06M	$0.49	40.63
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A

Summary

Amneal Pharmaceuticals beats Structure Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Structure Therapeutics compare to Lantheus?

Structure Therapeutics (NASDAQ:GPCR) and Lantheus (NASDAQ:LNTH) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

Structure Therapeutics presently has a consensus target price of $110.91, suggesting a potential upside of 334.26%. Lantheus has a consensus target price of $108.11, suggesting a potential upside of 7.95%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Structure Therapeutics is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.82
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

91.8% of Structure Therapeutics shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 5.5% of Structure Therapeutics shares are held by company insiders. Comparatively, 1.7% of Lantheus shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Lantheus has a net margin of 17.69% compared to Structure Therapeutics' net margin of 0.00%. Lantheus' return on equity of 28.10% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-25.56%	-24.31%
Lantheus	17.69%	28.10%	14.35%

In the previous week, Lantheus had 1 more articles in the media than Structure Therapeutics. MarketBeat recorded 3 mentions for Lantheus and 2 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 0.36 beat Lantheus' score of 0.00 indicating that Structure Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Lantheus	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Structure Therapeutics has a beta of -1.3, indicating that its stock price is 230% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market.

Lantheus has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A
Lantheus	$1.54B	4.24	$233.56M	$4.14	24.19

Summary

Lantheus beats Structure Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Structure Therapeutics compare to Liquidia?

Liquidia (NASDAQ:LQDA) and Structure Therapeutics (NASDAQ:GPCR) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

64.5% of Liquidia shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 25.6% of Liquidia shares are held by company insiders. Comparatively, 5.5% of Structure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Liquidia currently has a consensus price target of $83.69, indicating a potential upside of 205.67%. Structure Therapeutics has a consensus price target of $110.91, indicating a potential upside of 334.26%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Structure Therapeutics is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.25
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.82

In the previous week, Liquidia had 30 more articles in the media than Structure Therapeutics. MarketBeat recorded 32 mentions for Liquidia and 2 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 0.36 beat Liquidia's score of -0.12 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	4 Very Positive mention(s)	6 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Structure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Liquidia has a net margin of 30.74% compared to Structure Therapeutics' net margin of 0.00%. Liquidia's return on equity of 149.65% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
Structure Therapeutics	N/A	-25.56%	-24.31%

Liquidia has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	15.48	-$68.92M	$1.37	19.99
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A

Liquidia has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.3, indicating that its stock price is 230% less volatile than the broader market.

Summary

Liquidia beats Structure Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Structure Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GPCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GPCR vs. The Competition

Export

Metric	Structure Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.79B	$12.34B	$7.16B	$13.21B
Dividend Yield	N/A	2.64%	2.53%	16.36%
P/E Ratio	-25.54	797.58	274.13	26.16
Price / Sales	N/A	754.39	590.44	94.78
Price / Cash	N/A	85.97	76.38	53.09
Price / Book	1.02	10.71	11.21	6.34
Net Income	-$141.20M	$2.84B	$3.50B	$381.90M
7 Day Performance	-7.70%	-0.94%	-0.92%	-1.41%
1 Month Performance	-35.42%	-4.92%	-4.46%	-3.48%
1 Year Performance	-15.06%	-4.14%	6.94%	1.16%

Structure Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GPCR Structure Therapeutics	2.36 of 5 stars	$25.54 -0.5%	$110.91 +334.3%	-16.4%	$1.79B	N/A	N/A	281	Analyst Upgrade
CRNX Crinetics Pharmaceuticals	0.9045 of 5 stars	$84.95 flat	$83.44 -1.8%	N/A	$9.01B	$7.70M	N/A	210
BLTE Belite Bio	3.0412 of 5 stars	$166.41 +0.3%	$218.73 +31.4%	+96.8%	$6.71B	N/A	N/A	41
AMRX Amneal Pharmaceuticals	3.8749 of 5 stars	$20.51 +0.0%	$21.00 +2.4%	+93.5%	$6.54B	$3.02B	41.79	8,500	Analyst Downgrade
LNTH Lantheus	3.1606 of 5 stars	$99.37 -0.4%	$108.11 +8.8%	+91.2%	$6.49B	$1.54B	24.00	1,193

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GPCR) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Structure Therapeutics (GPCR) Competitors

GPCR vs. CRNX, BLTE, AMRX, LNTH, and LQDA

How does Structure Therapeutics compare to Crinetics Pharmaceuticals?

Summary

How does Structure Therapeutics compare to Belite Bio?

Summary

How does Structure Therapeutics compare to Amneal Pharmaceuticals?

Summary

How does Structure Therapeutics compare to Lantheus?

Summary

How does Structure Therapeutics compare to Liquidia?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GPCR vs. The Competition

Structure Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Structure Therapeutics (GPCR) Competitors

GPCR vs. CRNX, BLTE, AMRX, LNTH, and LQDA

How does Structure Therapeutics compare to Crinetics Pharmaceuticals?

Do institutionals & insiders believe in CRNX or GPCR?

Is CRNX or GPCR more profitable?

Does the media prefer CRNX or GPCR?

Which has more volatility and risk, CRNX or GPCR?

Which has stronger earnings & valuation, CRNX or GPCR?

Do analysts rate CRNX or GPCR?

Summary

How does Structure Therapeutics compare to Belite Bio?

Do analysts rate BLTE or GPCR?

Do insiders & institutionals believe in BLTE or GPCR?

Which has more risk & volatility, BLTE or GPCR?

Which has higher valuation & earnings, BLTE or GPCR?

Is BLTE or GPCR more profitable?

Does the media prefer BLTE or GPCR?

Summary

How does Structure Therapeutics compare to Amneal Pharmaceuticals?

Which has more risk and volatility, AMRX or GPCR?

Do insiders and institutionals hold more shares of AMRX or GPCR?

Is AMRX or GPCR more profitable?

Do analysts rate AMRX or GPCR?

Does the media refer more to AMRX or GPCR?

Which has better earnings and valuation, AMRX or GPCR?

Summary

How does Structure Therapeutics compare to Lantheus?

Do analysts recommend GPCR or LNTH?

Do insiders & institutionals hold more shares of GPCR or LNTH?

Is GPCR or LNTH more profitable?

Does the media prefer GPCR or LNTH?

Which has more volatility and risk, GPCR or LNTH?

Which has stronger earnings and valuation, GPCR or LNTH?

Summary

How does Structure Therapeutics compare to Liquidia?

Do insiders and institutionals have more ownership in LQDA or GPCR?

Do analysts prefer LQDA or GPCR?

Does the media refer more to LQDA or GPCR?

Is LQDA or GPCR more profitable?

Which has preferable earnings & valuation, LQDA or GPCR?

Which has more volatility and risk, LQDA or GPCR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GPCR vs. The Competition

Structure Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools